Kura Oncology rises as kidney cancer combo shows early promise

Kura Oncology

17/04/2026 11:16

** Shares of biotech firm Kura Oncology KURA.O rise 3.5% to $9.25 premarket

** Company says early-stage data showed its experimental drug darlifarnib plus cabozantinib shrank tumors in patients with advanced kidney cancer

** Clear cell renal cell carcinoma is the most common form of kidney cancer

** Company says 44% of patients saw tumors shrink and 94% had disease control, meaning the cancer did not worsen

** Tumor shrinkage seen even in patients whose cancer had stopped responding to cabozantinib before

** The drug combination was safe and tolerable across tested doses - KURA

** The study has moved into the next stage to see if darlifarnib can help overcome resistance to cabozantinib - company

** As of last close, shares down ~14% this year

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))